908 Devices Inc. (MASS)
NASDAQ:MASS
Want to see MASS full AI Analyst Report?
Top Page
908 Devices
(NASDAQ:MASS)
Select Model
Select Model
Rating:56Neutral
Price Target:
$7.50
▲(20.97% Upside)
Action:Reiterated
Date:05/09/26
The score is held back most by weak financial performance (ongoing losses and cash burn) and limited valuation support (negative P/E, no dividend). Offsetting this, the latest earnings call was constructive with raised 2026 guidance, improving adjusted profitability, and a strong cash position, while technicals show positive trend momentum but with overbought risk.
Positive Factors
Balance Sheet Strength
A large cash reserve and minimal leverage provide durable financial flexibility to fund R&D, commercial expansion, and M&A without near-term refinancing. This cushions operations during continued cash burn and lowers solvency risk, supporting multi-quarter execution of growth plans.
Negative Factors
Persistent Cash Burn
Sustained negative operating and free cash flow mean the business consumes cash to grow, increasing dependence on existing reserves or external financing. Until operating profitability or positive cash flow is achieved, capital allocation and growth pacing remain constrained.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
A large cash reserve and minimal leverage provide durable financial flexibility to fund R&D, commercial expansion, and M&A without near-term refinancing. This cushions operations during continued cash burn and lowers solvency risk, supporting multi-quarter execution of growth plans.
Read all positive factors
908 Devices (MASS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$269.23M
Dividend YieldN/A
Average Volume (3M)259.99K
Price to Earnings (P/E)―
Beta (1Y)1.02
Revenue Growth-5.89%
EPS Growth53.75%
CountryUS
Employees246
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.98
Shares Outstanding37,813,620
10 Day Avg. Volume223,516
30 Day Avg. Volume259,987
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.32
Price to Sales (P/S)3.38
P/FCF Ratio-7.72
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue3.67
Enterprise Value/Gross Profit7.49
Enterprise Value/Ebitda-11.03
Forecast
1Y Price Target
$10.00Price Target Upside61.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$65.94M
908 Devices Business Overview & Revenue Model
Company Description
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry (Mass Spec) devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, industrial ...
How the Company Makes Money
908 Devices primarily makes money by selling analytical instruments (notably compact mass spectrometry systems) to customers in life sciences, applied markets, and government-related end users. A second revenue stream comes from recurring purchase...
908 Devices Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call conveys a predominantly positive operational and strategic trajectory: revenue and handheld product growth, improved margins, reduced adjusted EBITDA loss, strong cash position, and the strategic acquisition of NIRLAB that accelerates recurring revenue and expands addressable markets. Key near-term negatives include a wider GAAP net loss driven by a noncash contingent consideration revaluation, a decline in recurring revenue this quarter driven by service reductions, and a modest near-term EBITDA drag from NIRLAB as it is integrated and scaled in the U.S. On balance, the highlights (revenue growth, margin expansion, device momentum, strengthened guidance, cash balance, and accretive M&A strategy) significantly outweigh the lowlights, which are largely one-time accounting charges or manageable integration risks.Positive Updates
Revenue Growth
Total revenue of $13.4M in Q1 2026, up 14% year-over-year from $11.8M.
Negative Updates
Net Loss Widened
Net loss from continuing operations was $12.0M in Q1 2026 versus $9.8M prior year, primarily driven by a $3.9M noncash revaluation of contingent consideration.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth
Total revenue of $13.4M in Q1 2026, up 14% year-over-year from $11.8M.
Read all positive updates
Company Guidance
908 Devices raised its 2026 outlook to $67–$70 million in total revenue (a $2.5M increase to prior guidance), implying 19%–25% growth vs. 2025, with handheld product & service revenue expected to be $62–$64 million (up ~18%–21% y/y), OEM/funded partnerships ~ $3 million, and AVCAD program revenue $2–$3 million (likely in H2); management expects adjusted gross margins in the mid‑to‑high‑50% range and to reduce the adjusted EBITDA loss to the mid‑single‑digit millions (Q1 adjusted EBITDA was –$2.5M, a 45% improvement vs –$4.6M a year ago), while noting NIRLAB will contribute roughly $2.5M of revenue in the remaining eight months of 2026 (with ~40%–50% recurring mix and >99% subscription retention) but be ~ $1M of adjusted EBITDA headwind in 2026 and grow to >$5M revenue and adjusted‑EBITDA‑positive in 2027; the NIRLAB acquisition consideration is $15M upfront ($13M cash, $2M equity) plus up to $8M additional equity contingent on milestones, and the company exited Q1 with $111.7M in cash and minimal cash burn in the quarter.908 Devices Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
72
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 57.80M | 56.20M | 59.63M | 50.23M | 46.85M | 42.21M |
| Gross Profit | 28.32M | 26.80M | 29.93M | 25.32M | 26.02M | 23.23M |
| EBITDA | -19.23M | -19.71M | -43.88M | -40.27M | -31.82M | -20.76M |
| Net Income | -35.89M | -36.64M | -72.21M | -36.40M | -33.56M | -22.17M |
Balance Sheet | ||||||
| Total Assets | 186.69M | 190.07M | 159.48M | 202.98M | 242.59M | 260.91M |
| Cash, Cash Equivalents and Short-Term Investments | 111.74M | 112.97M | 69.60M | 145.68M | 188.42M | 224.07M |
| Total Debt | 4.47M | 16.71M | 6.61M | 5.95M | 19.51M | 20.85M |
| Total Liabilities | 52.52M | 46.37M | 44.88M | 37.49M | 51.99M | 46.30M |
| Stockholders Equity | 134.17M | 143.70M | 114.59M | 165.49M | 190.60M | 214.60M |
Cash Flow | ||||||
| Free Cash Flow | -8.42M | -24.64M | -30.85M | -27.10M | -22.98M | -29.82M |
| Operating Cash Flow | -7.58M | -23.69M | -30.25M | -25.06M | -20.93M | -29.08M |
| Investing Cash Flow | -1.56M | 50.75M | -46.32M | -26.40M | -15.81M | -737.00K |
| Financing Cash Flow | -2.56M | -697.00K | -376.00K | -15.94M | 1.18M | 94.72M |
908 Devices Technical Analysis
Positive
6.20
Price Trends
6.84
Positive
6.55
Positive
6.70
Positive
Market Momentum
0.05
Positive
53.06
Neutral
37.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MASS, the sentiment is Positive. The current price of 6.2 is below the 20-day moving average (MA) of 7.18, below the 50-day MA of 6.84, and below the 200-day MA of 6.70, indicating a bullish trend. The MACD of 0.05 indicates Positive momentum. The RSI at 53.06 is Neutral, neither overbought nor oversold. The STOCH value of 37.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MASS.
908 Devices Risk Analysis
908 Devices disclosed 64 risk factors in its most recent earnings report. 908 Devices reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
908 Devices Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $269.23M | -4.71 | -25.50% | ― | -5.89% | 53.75% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $321.57M | -2.36 | -130.00% | ― | 71.91% | 14.73% | |
47 Neutral | $124.36M | -2.36 | -35.17% | ― | 6.85% | -90.71% | |
47 Neutral | $132.92M | -1.41 | -47.09% | ― | 15.40% | -25.87% | |
47 Neutral | $511.40M | -7.45 | -20.77% | ― | 3.61% | -568.29% | |
45 Neutral | $211.89M | 33.49 | 162.57% | ― | 39.64% | -25.99% |
* Healthcare Sector Average
MASS
908 Devices
7.28
2.48
51.67%
SENS
Senseonics Holdings
6.34
-3.75
-37.19%
QTRX
Quanterix
2.69
-2.16
-44.54%
NNOX
Nano-X Imaging
1.84
-3.29
-64.13%
TLSI
TriSalus Life Sciences
3.26
-2.30
-41.37%
CTKB
Cytek Biosciences
4.01
1.59
65.70%
908 Devices Corporate Events
Business Operations and StrategyFinancial DisclosuresM&A Transactions
908 Devices Completes NIRLAB Acquisition, Advances Growth Strategy
Positive
May 6, 2026
908 Devices Inc., a Burlington, Mass.–based small‑cap growth company, develops handheld chemical analysis devices that combine advanced analytical technologies with software and machine learning to address critical health, safety and d...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.